Oxford BioDynamics announces US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) foroncology

Checkpoint Inhibitor Response Test (EpiSwitch® CiRT) for oncology

• First-of-its-kind precision medicine test to predict a cancer patent's response

to an Immune Checkpoint Inhibitor (ICI)

• Provides guidance to support critical treatment decisions on beginning or

continuing treatment with this essential class of cancer therapeutic

• A significant advancement in harmonizing the prediction of response to ICI

treatment, as demanded by the FDA and oncologists

• Clinically validated blood test now available to oncologists across the US

• EpiSwitch CiRT delivers best in class performance: 93% sensitivity, 82%

specificity, 85% accuracy

Oxford, UK - 25 February 2022 - Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on its EpiSwitch 3D genomics platform, has announced

the successful clinical validation and US launch of its Checkpoint Inhibitor Response Test (EpiSwitch® CiRT). The first-of-its-kind clinical blood test predicts the likelihood of a cancerpatient's response to an essential, widely used class of therapeutics - Immune Checkpoint Inhibitors (ICIs) - including anti-PD-L1 and anti-PD-1 immunotherapies. The robust EpiSwitch qPCR blood test has demonstrated best-in-class performance, with high sensitivity (93%), specificity (82%), and accuracy (85%) across several ICI's from multiple pharmaceutical companies and more than 15 key oncological indications. OBD's EpiSwitch CiRT enables doctors to make an informed decision on whether to recommend beginning or continuing treatment with an ICI. Using a routine blood test rather than an invasive biopsy, CiRT offers fast, personalized guidance. OBD has partnered with NEXT Molecular Analytics (VA, USA) to clinically validate EpiSwitch CiRT within its high complexity CLIA-certified laboratory. Delivering the CiRT as an LDT is consistent with OBD and NEXT's aim of getting these important tests into the hands of physicians to meet demand

and help patients as quickly as possible.

Tom Reynolds, President of NEXT Molecular Analytics said: "We are excited to be working with Oxford BioDynamics to bring this novel and sensitive Checkpoint Inhibitor Response test to oncologists and their patients in the US market. The EpiSwitch CiRT will provide oncologists with a powerful new tool to help manage complex treatment decisions with their patients." EpiSwitch CiRT was built using OBD's well-established EpiSwitch 3D genomics platform, used to discover the most important drivers that determine a patient's response to ICIs. For each patient, CiRT captures a personal fingerprint of their complex cancer genomic and immune system interactions. The EpiSwitch platform has been leveraged by leading pharma and clinical research teams for practical patient stratification in prognostic, predictive and early diagnostic applications across immuno-oncology, autoimmune and neurodegenerative indications. The US launch of CiRT follows the earlier launch of EpiSwitch CST (COVID Severity Test) and expands OBD's immune health test offerings. Further information about the EpiSwitch® CiRT is available at: www.myCiRT.com.